Is ARA-290 the same as EPO?

No. ARA-290 is an 11-amino-acid peptide designed from one region of EPO. In studies it did not raise red blood cell counts the way EPO does.

Has ARA-290 been tested in humans?

Yes, in a few small phase 2 trials, mainly in people with sarcoidosis-related small fiber neuropathy and type 2 diabetes. The results were encouraging on some measures, but the trials were small and short.

Cibinetide is the official nonproprietary name for ARA-290.

What is ARA-290 researched for?

Mainly small fiber neuropathy and nerve pain, plus diabetes complications and tissue protection in animal models of eye, kidney and nerve injury.

ARA-290 (Cibinetide) Peptide: What It Is, Research and Side Effects

What is ARA-290?

ARA-290 is a lab-made peptide based on a short stretch of erythropoietin known as helix B. EPO is best known as the kidney hormone that tells bone marrow to make red blood cells, and as a medicine for some types of anemia. Researchers including Michael Brines and Anthony Cerami reported that EPO also protects stressed tissue, and proposed that this effect runs through a different receptor than the one used for red blood cell production.

ARA-290 was developed to target that tissue-protective receptor alone. Its official nonproprietary name is cibinetide. It is an investigational compound, not an approved medicine, and it has been studied mainly for small fiber neuropathy, a type of damage to the thinnest nerve fibers that can cause burning pain and numbness.

How does ARA-290 work?

ARA-290 is thought to act on what researchers call the innate repair receptor. This receptor is made of the EPO receptor paired with another protein called the beta common receptor, or CD131. It appears to switch on in tissue that is injured or inflamed. When activated, it is linked in lab and animal studies to lower levels of inflammatory signals, less cell death and better survival of nerve and other tissue.

Because ARA-290 does not appear to activate the standard EPO receptor pair that drives red blood cell production, in studies it did not raise red blood cell counts the way EPO does. Researchers have also reported that it stays in the bloodstream only briefly, while its effects in animal studies seemed to last much longer. Exactly why is not fully understood.

What has research looked at?

Sarcoidosis nerve damage: Small randomized, placebo-controlled trials in people with sarcoidosis-related small fiber neuropathy reported improvements in some pain and symptom measures and in corneal nerve fiber measures. Other outcomes showed no clear change, and the trials were short.
Type 2 diabetes: A small placebo-controlled trial in people with type 2 diabetes and nerve symptoms reported improvements in some nerve symptom scores and some blood sugar measures over a few weeks. Larger, longer trials have not been published.
Nerve injury in animals: Rodent studies of nerve injury and diabetic nerve damage reported less pain behavior and better nerve preservation in treated animals.
Eyes and kidneys: Animal studies of retinal damage and kidney injury reported protective effects. These are early, preclinical findings.
Wounds and inflammation: Some animal work explored wound healing and inflammatory models, with encouraging but early results.

ARA-290 has more human data than many peptides discussed online, but the trials were small, short and run by a limited group of researchers. Promising early results are not the same as proof that it helps a given condition, and larger confirmatory trials have not been published.

ARA-290 vs EPO

EPO and ARA-290 are often mentioned together, but they behave differently. EPO is thought to act on two receptor systems: one that drives red blood cell production and one tied to tissue protection. As a drug, EPO can raise red blood cell levels too far, which has been linked to blood clots and high blood pressure. ARA-290 is a much smaller piece built to engage only the tissue-protective system, and in trials it did not raise hemoglobin.

Side effects and cautions

In the small human trials published so far, ARA-290 was generally reported to be well tolerated, with no serious safety signals highlighted. Those trials involved few people over short periods, so less common or long-term side effects would not have been detected. Mild effects such as nausea or digestive upset are mentioned in informal sources but are not well documented. Anyone with health questions should talk to a qualified clinician.

Limited data: Human safety information comes from a small number of short trials.
Immune effects: ARA-290 is studied for calming inflammatory signals. How that affects fighting active infections is not well studied.
Cancer history: EPO has raised concerns about tumor growth in some cancer patients. Whether ARA-290 shares any such risk is unknown, so it remains a theoretical question.
Pregnancy and breastfeeding: There are no safety data.